Peptide education
Pinealon
EDR · Glu-Asp-Arg
Pinealon is a three-amino-acid peptide, Glu-Asp-Arg, from the same Russian bioregulator program that produced Epitalon. Despite the name, it does not come from the pineal gland: it descends from cortexin, the cortex extract lineage, while Epitalon is the one that actually derives from the pineal. Online it is a sleep and REM peptide. The human evidence behind that reputation is one line in a symptom table: a 2006 clinical report in 74 patients with mixed CNS disorders where sleep-disturbance complaints fell on a checklist, with no polysomnography, no validated sleep scale, and unclear blinding. Everything else is mechanism and animal work. A REM-sleep peptide, this is not.
Pinealon's sleep reputation rests on a single symptom-checklist row in one old clinical report. The mechanism literature is real neurobiology; the REM and cognition claims are that one row, amplified.
Overview
Quick answer
Pinealon is not Epitalon. Pinealon is EDR and is mainly tied to neurobiology and cognition claims. Epitalon is AEDG and is usually discussed through pineal, melatonin, circadian, telomere, and longevity claims. They may appear together in online stack discussions, but the current sources leave combination effects unanswered: sleep, cognition, safety, and attribution.
What is Pinealon?
A tripeptide, Glu-Asp-Arg, from the Russian bioregulator lineage. The literature frames it around gene expression, oxidative stress, and neuronal aging rather than a defined sleep-drug pathway. It is an investigational compound with no FDA-approved use.
Why do people look it up?
Mostly for sleep: REM, dreams, next-day recovery after a bad night, plus brain fog, memory, and mood. The sourcing is thinner than the curiosity. The sleep claims trace to a symptom-table item, and the cognition claims trace to older observations inside a review whose primary papers have not been verified.
What use pattern appears in the older report?
Oral, and small: 0.100 mg capsules, 1 to 2 capsules two to three times daily before meals, for 10 to 20 days, with a repeat course after 3 to 6 months. That works out to 0.2 to 0.6 mg per day in a 2006 report that no registered trial has followed up.
What route and stack claims appear in public discussion?
People inject it subcutaneously at 5 to 10 mg per day in 10-day courses, take capsules, or stack it with Epitalon. The injectable pattern uses a different route at many times the studied oral amount, and the stack has never been tested, so treat all of it as reported practice.
Which Pinealon claims require separate evidence?
All of them, separately. Sleep quality, REM, cognition, neuroprotection, and the Epitalon stack are different questions with different evidence, and right now the strongest source behind each is a cell, a rat, or a checklist.
Reported practice
Commonly reported protocol
Community bioregulator courses. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
The PubMed review, rat hyperhomocysteinemia study, and induced-neuron paper support a mechanism-level explanation of EDR biology and preclinical neuroprotection. They are not human cognition or sleep-benefit studies.
One summarized clinical report in mixed CNS disorders included a sleep-disturbance symptom item. It did not use polysomnography, actigraphy, ISI, PSQI, or another standard sleep measure, and randomization and blinding were not clear in the available report.
A ClinicalTrials.gov search for Pinealon did not return matching trial records. That result is a registry check, not a measure of benefit or safety.
REM, poor-sleep-night, occasional-use, and next-night-effect claims appear in public discussion rather than controlled sleep evidence. They are too weak to turn into timing, dose, route, cycle, or stack instructions.
Consumer products sold as Pinealon can differ by identity, amount, sterility, storage, impurity profile, and route. Mechanism papers do not verify a vial, capsule, spray, or compounded product.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Pinealon improves cognition or protects the brain. | The available human evidence does not include a direct cognition outcome. The 2020 review mentions older human cognition observations, but primary clinical reports still need tracing before that claim can be upgraded. | EDR sources discuss gene-expression regulation, oxidative stress, apoptosis, MAPK/ERK signaling, serotonin-related pathways, and neuronal aging. Rat and induced-neuron studies explain why the neuroprotection idea exists. | Online and market discussions often use Pinealon for brain clarity, mood, learning, and recovery language. Those reports show what people are looking for, but they do not replace controlled human evidence. | Worth discussing as a neurobiology topic, but direct cognition and neurorecovery outcome evidence is still limited. |
| Pinealon improves sleep quality or REM sleep. | The sleep-adjacent human evidence comes from a weak clinical report in mixed CNS disorders. "Sleep disturbance" decreased in the Pinealon group, but the outcome was a symptom item rather than a standard sleep measure. | General neuronal stress and oxidative-stress mechanisms could matter for sleep indirectly, but Pinealon-specific circadian, melatonin, or sleep architecture mechanisms are not well demonstrated in the cited EDR material. | Public discussion includes REM, vivid-dream, poor-sleep-night, and inconsistent sleep-response reports. Some reports are framed as calming; others sound activating or disruptive. | A narrow historical sleep-symptom signal exists, but it is too limited to call Pinealon a sleep treatment or to support as-needed use patterns. |
| Pinealon has a standard cycle or repeat-course protocol. | The old CNS clinical report includes short oral-course details, and market material contains cycle and repeat-use claims. Those details show what has been reported, but they do not establish a modern route, repeat interval, or stack plan. | Mechanism papers do not give route, amount, frequency, duration, or repeat-course safety. | Public-discussion and market material includes cycle language, but that material does not justify exact timing, repeat-course, or stack instructions. | The concrete pattern is the old oral report. Newer cycle claims remain unverified claims rather than a settled schedule. |
| Pinealon and Epitalon are a supported stack. | The cited human material does not test Pinealon plus Epitalon as a combined intervention for sleep, cognition, circadian rhythm, REM, or longevity. | Pinealon/EDR and Epitalon/AEDG have different source profiles. Mechanistic adjacency cannot tell whether combining them is useful or safe. | Combination claims appear in market and online discussion, but attribution becomes harder when sleep, circadian, cognition, and longevity claims are blended. | Pinealon and Epitalon need separate evaluation. The chemistry and study history support distinction, not a stack recommendation. |
| A Pinealon label settles the product-identity issue. | Human and preclinical literature does not verify consumer-product identity, sterility, concentration, stability, or lot-to-lot consistency. | A sequence name is only the starting point. Biological interpretation depends on the actual material, route, dose form, impurities, degradation, and storage conditions. | Consumer discussions may blur capsules, injectable vials, sprays, and sublingual products. Those product-identity and product-quality issues still need answers. | Product quality has to be evaluated separately from the EDR literature and the label name. |
Bottom line
Main takeaway
Pinealon is a three-amino-acid peptide sold on sleep and brain claims. Its best human evidence is a symptom-checklist improvement in one old report; everything else is mechanism work.
Notice the source types: one old oral report, a rat study, a cell study, a review, and forums. The injectable 5 to 10 mg community courses have no studied counterpart at any dose.
Missing: the primary papers behind the review's older cognition mentions, any standard sleep endpoint, human pharmacokinetics, and any registered trial. The 2006 report's sleep row is the whole human sleep dataset.
Identity
What it is
Pinealon is the tripeptide Glu-Asp-Arg, EDR, a short-peptide bioregulator from the same research lineage as Epitalon. Its proposed identity is a gene-expression and oxidative-stress modulator in neurons, not a sleep drug.
The human record is one 2006 clinical report: 42 patients with mixed CNS disorders given oral Pinealon alongside conventional therapy, 32 comparison patients, and a symptom checklist. Sleep disturbance fell from 52.6% to 26.1% in the Pinealon group against 39.2% in the comparison group, with no standard sleep measurement and unclear trial protections. That row is the most-cited human sleep fact about Pinealon.
Around that row sits real preclinical work: EDR effects on gene expression and oxidative stress, a rat model of cognitive damage, and an induced-neuron aging study. It explains why neuroprotection claims exist. It does not explain how Pinealon became a REM peptide, because nothing measured REM.
How people talk about it online
The internet's Pinealon is a sleep and dreams peptide: REM claims, vivid-dream reports, occasional use after a bad night, stacks with Epitalon. Individual reports point in opposite directions, calming for some, activating or early-waking for others, which is what you expect when a compound has no defined human effect.
The market sells capsules and injectable vials under course-based schedules, typically 10 days at 5 to 10 mg daily by injection, repeated once or twice a year. The studied pattern was oral and a fraction of that amount, so the popular schedules are a market invention wearing a study's clothes.
Use context
Routes, doses, and cycle patterns
Pinealon has one concrete oral pattern from an older study. Other route, amount, timing, cycle, repeat-course, and combined-use claims show up online, but the strongest concrete details are still the old oral-report numbers.
Human studies and product labels
Older CNS clinical report
- Purpose
- Mixed central nervous system complaints including memory, attention, mental work capacity, and a sleep-disturbance symptom item
- Context
- Older controlled clinical report; randomization and blinding are not specified in the available summary
- Route
- Oral capsule or tablet
- Amount
- 0.100 mg active substance per capsule or tablet; 1 to 2 capsules reported per dose
- Frequency
- 2 to 3 times per day before meals in the summarized report
- Duration
- 10 to 20 days, depending on severity in the report
The Pinealon group was reported as 42 patients, with a 32-patient conventional-therapy comparison group. Sleep disturbance fell from 52.6% before treatment to 26.1% after Pinealon plus conventional therapy, while the comparator group improved to 39.2%. The sleep item was a symptom checklist result, so it cannot distinguish insomnia, circadian phase, fragmented sleep, pain, mood, or neurologic recovery.
Real-world discussion
Community bioregulator courses
- Purpose
- Cognition and neuroprotection discussion
- Context
- Clinics, forums, and bioregulator vendors
- Route
- Subcutaneous injection, with oral capsule versions also marketed
- Amount
- Commonly around 5 to 10 mg per day by injection, or one to two capsules daily for oral versions
- Frequency
- Once daily during a course
- Duration
- Commonly 10 day courses, repeated once or twice per year
Pinealon follows the same course-based Khavinson pattern as epitalon, and the supporting literature is almost entirely from that lineage. Reported as context, not a recommendation.
What varies
- Goal: cognition, REM sleep, poor-sleep-night recovery, and neuroprotection claims need their own evidence checks.
- Route: oral report context says little about exposure, sterility, or preservatives in injectable, sublingual, or spray products.
- Amount: one old report lists 0.100 mg per capsule or tablet, while current sources do not give a consumer-market amount.
- Frequency and duration: the 10-to-20-day oral course comes from the published study context.
- Product: identity, purity, sterility, stability, storage, and route-specific quality remain separate from mechanism claims.
Human data
Human evidence
One old clinical report is the entire human dataset: 42 Pinealon patients and 32 comparison patients, oral capsules for 10 to 20 days, outcomes on a symptom checklist. Its sleep finding, a drop in sleep-disturbance complaints, came without polysomnography, actigraphy, or any validated sleep scale, and the report's trial protections are unclear. No registered Pinealon trial exists, and the cognition claims rest on unverified older observations cited in a review. The mechanism and preclinical work is the stronger part of this page, and it still is not human outcomes.
Evidence maturity
Pinealon's literature is mostly mechanism and preclinical; the single old human report is too weak to carry modern sleep or cognition claims.
EDR gene-expression, oxidative-stress, rat, and induced-neuron studies explain the neuroprotection hypothesis.
One 2006 controlled report in mixed CNS disorders tracked a sleep-disturbance symptom item without standard sleep endpoints.
A ClinicalTrials.gov search returned no Pinealon records, and no direct human cognition, REM, or sleep-architecture trials exist.
Bioregulator-market capsules and injectable vials circulate with unverified identity, route, and quality.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Pinealon CNS clinical report | 42 Pinealon-group patients with mixed CNS disorders and 32 comparison patients receiving conventional therapy alone | Controlled clinical report; randomization and blinding not clear from the public summary | Oral Pinealon capsule or tablet described as a biologically active food additive in the public summary | Sleep-disturbance complaints reportedly decreased from 52.6% before treatment to 26.1% after Pinealon plus conventional therapy; the comparison group improved to 39.2%. | Mixed neurologic population, unclear trial protections, symptom-checklist endpoint, no polysomnography, no actigraphy, no ISI or PSQI, and no way to separate sleep-specific effects from broader neurologic or mood changes. | Weak human context |
| EDR mechanism and Alzheimer's-pathogenesis review | Review-level source discussing EDR mechanisms and older cognition observations | PubMed-indexed review | Review-level mechanism context, not a tested consumer product | The review supports discussion of EDR gene-expression and neuroprotection hypotheses, but not a direct sleep, REM, or cognition claim. | The review mentions older cognition observations, but the underlying primary reports still need checking before human cognition effects can be described confidently. | Mechanism-heavy |
| Rat prenatal hyperhomocysteinemia study | Rat offspring exposed to prenatal hyperhomocysteinemia | Preclinical animal study | Laboratory preclinical Pinealon context | The study is used for cognitive and oxidative-stress context in a rat model, not for human sleep or neurorecovery efficacy. | Animal offspring findings do not answer human route, amount, sleep outcomes, or clinical benefit. | Preclinical |
| Short peptides in fibroblast-derived induced neurons | In vitro induced-neuron model including EDR and AEDG | Cell-model mechanism study | Laboratory mechanism context | The study supports induced-neuron and cellular-aging mechanism discussion, not a clinical sleep or longevity claim. | Cell-model results do not answer symptom improvement, dose response, route equivalence, or safety in people. | Preclinical |
| ClinicalTrials.gov Pinealon search | Public trial registry search | Registry no-match check | Trial registry context | The exact Pinealon search did not return matching ClinicalTrials.gov records in the available source. | A no-match registry search cannot rule out every possible study, but it shows that no current registry-backed program was found in that database search. | Registry context |
Use context
Reported use context
Reported Pinealon use splits into one old oral study pattern and broader public discussion. Concrete numbers are included only where a study or label gives them; market or anecdotal protocols are described separately so they are not confused with the study pattern.
Study and label context
0.100 mg active substance per capsule or tablet; 1 to 2 capsules 2 to 3 times per day before meals for 10 to 20 days. This schedule comes from an old report and should remain historical context.
A ClinicalTrials.gov search for Pinealon did not return matching trial records. That no-match result means only that no matching ClinicalTrials.gov record was found; it does not measure benefit or safety.
Real-world discussion
Public discussion mentions REM sleep, sleep quality, activation, early waking, and inconsistent individual responses. Community descriptions commonly converge on 10 day courses of roughly 5 to 10 mg per day by injection, or one to two capsules daily for oral versions, repeated once or twice per year. These reports describe public claims, but they do not give a dose, timing, route, cycle, repeat interval, stack, or sleep-loss replacement strategy.
Pinealon and Epitalon are sometimes discussed together for sleep, circadian, REM, cognition, or longevity-adjacent goals. The cited sources support separating the two peptides; they leave unanswered what the combination adds or what safety tradeoffs it creates.
Cautions
Safety and unknowns
- Physician and clinic reports add two practical cautions seen outside formal studies: small blood-sugar drops in some users, and vivid dreams that can be distressing for people prone to nightmares. Neither is quantified in the literature.
- Route-specific safety starts with product quality. The old oral study says little about sterility, concentration, preservatives, or exposure from injectable, sublingual, spray, compounded, or research-vial products.
- The cited material does not answer long-term and repeat-course safety, especially for chronic or intermittent real-world use.
- The old CNS report states no adverse effects in that setting, but the report is not a strong safety program or a substitute for modern adverse-event collection.
- Sleep effects are hard to interpret because reported responses may reflect mood, neurologic recovery, pain, activation, circadian timing, or unrelated changes rather than Pinealon-specific sleep biology.
- Product identity, purity, concentration, sterility, endotoxin, aggregation, degradation, and storage remain central uncertainties for consumer-market products.
Product quality
A vial label is only a starting point
A product sold as Pinealon may not match the EDR material in a mechanism paper or the old oral clinical report. Route, dose form, manufacturing controls, storage, and testing change the risk.
Injectable Pinealon claims deserve a separate quality check because sterility, endotoxin, particulate matter, concentration, and handling are practical product issues, not mechanism arguments.
Identity
The name Pinealon or EDR cannot confirm the peptide sequence, salt form, purity, degradation profile, or actual amount in a product.
Route and dose form
Oral capsules, tablets, sprays, sublingual products, and injectable vials are not interchangeable.
Sterility and endotoxin
Any injectable route adds risks left open by PubMed mechanism papers or anecdotal sleep reports.
Stability and storage
Small peptides can degrade or vary by storage and handling; the reviewed material does not verify consumer-market lot stability.
Mechanism
How it is proposed to work
Pinealon's proposed mechanism is mostly a neurobiology story. EDR sources discuss changes in gene expression, oxidative-stress handling, apoptosis, MAPK/ERK signaling, serotonin-related pathways, and age-related neuronal stress. Those mechanisms can explain why cognition and neuroprotection claims exist, but they do not show whether Pinealon improves sleep, REM, circadian function, or human cognition.
The 2020 EDR review summarizes mechanism claims around gene expression and Alzheimer's-pathogenesis hypotheses, but it is not a sleep protocol source.
The rat hyperhomocysteinemia study supports preclinical cognitive and oxidative-stress discussion in a specific animal model.
The induced-neuron study supports cellular aging and neuroprotection plausibility for short peptides including EDR, but cell models are not clinical sleep or cognition outcomes.
Pinealon's sleep evidence is indirect. A weaker clinical report includes a sleep-disturbance symptom item, while stronger direct sleep tools and sleep-architecture data are not present.
FAQ
Common questions
Is there Pinealon sleep guidance?
No. Available evidence is not strong enough for a dose, timing, injectable-use, or as-needed sleep strategy.
Should Pinealon be combined with Epitalon?
Pinealon and Epitalon have different claim profiles, and combined-use claims remain anecdotal or market-reported until stronger sources are available.
Details
Technical details
Sources
References
- 1.
doi:10.3390/molecules26010159 PMID:33396470 Accessed 2026-06-08.
Review of Glu-Asp-Arg/EDR mechanisms and neuroprotection claims; useful for mechanism mapping, not a sleep protocol source.
- 2.
PubMed. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia 2012.
PMID:22567179 Accessed 2026-06-08.
Rat offspring study reporting cognitive and oxidative-stress outcomes; preclinical support only.
- 3.
PubMed. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes 2024.
doi:10.3390/ijms252111363 PMID:39518916 Accessed 2026-06-08.
In vitro induced-neuron study including EDR and AEDG; supports mechanism discussion but not clinical sleep or longevity claims.
- 4.
ClinicalTrials.gov. ClinicalTrials.gov search for Pinealon 2026.
Accessed 2026-06-09.
No matching Pinealon clinical trial records were returned by this exact Pinealon registry search; this is registry context, not direct sleep evidence.
- 5.
PubMed. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties 2025.
doi:10.3390/ijms26062691 PMID:40141333 Accessed 2026-06-08.
Review article for Epitalon/AEDG mechanism and translational context; claims still require evidence-type separation.
- 6.
Other. Pinealon clinical report in patients with central nervous system disorders 2006.
Accessed 2026-06-16.
Local reviewed sources summary of a 2005-2006 controlled clinical report in mixed CNS disorders; includes an oral short-course regimen and a symptom-table sleep-disturbance endpoint, but it is not a standalone peer-reviewed sleep trial.